The efficacy and safety of ketamine for depression in patients with cancer: A systematic review

Azari, Leila; Hemati, Homa; Tavasolian, Ronia; Shahdab, Sareh; Tomlinson, Stephanie M.; Bobonis Babilonia, Margarita; Huang, Jeffrey; Tometich, Danielle B.; Turner, Kea; Jim, Heather S.L.; Tabriz, Amir Alishahi

doi:10.1016/j.ijchp.2023.100428

Cited by 5 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, ketamine boasts a rapid onset of action and a robust impact on depression, rendering it a valuable option for individuals grappling with treatment-resistant depression [27]. Moreover, investigations have revealed that a subanesthetic dose of S-ketamine yields superior effects on both pain and depression compared to racemic ketamine in patients with cancer [30]. Overall, ketamine has showcased efficacy and safety across a spectrum of clinical applications, with its potential for depression treatment particularly salient.…”

Section: Ketaminementioning

confidence: 99%

Exploring Ciprofol Alternatives: A Comprehensive Review of Intravenous Anesthesia Options

Durai Samy,

Taksande

2024

Cureus

View full text Add to dashboard Cite

Ciprofol is a recently developed, short-acting γ-aminobutyric acid receptor agonist sedative that is more potent than propofol. Still, there have been few clinical studies of this agent to date. This review explores alternative intravenous anesthesia options to ciprofol, considering their pharmacology, clinical efficacy, safety profile, and practical considerations. While ciprofol offers advantages such as rapid onset and predictable offset, concerns regarding its safety profile and individual variability in response have prompted the search for alternatives. Propofol, etomidate, ketamine, and dexmedetomidine are discussed as established options, each with unique characteristics and potential benefits. Emerging agents, including remimazolam, sufentanil, alfaxalone, and brexanolone, are examined for their potential role in anesthesia management. Recommendations for future research include large-scale comparative studies, optimization of dosing strategies, and personalized approaches guided by pharmacogenomic insights. Ultimately, the future of intravenous anesthesia lies in a multifaceted approach that integrates evidence-based practices, technological innovations, and individualized patient care to enhance safety, efficacy, and patient satisfaction across the perioperative continuum. Collaboration among stakeholders will be crucial in advancing the field and shaping the future landscape of intravenous anesthesia options.

show abstract

Section: Ketaminementioning

confidence: 99%